Introduction
A trophic alveolar bone is one of the major obstacles for dental implant therapy and there are a large number of patients without sufficient bone volume. For patients with severe bone atrophy, autologous bone grafts have been performed. 1 However, even the amount of harvesting bone is small, the procedure is accompanied by swelling and pain of the donor site. 2 Although bioartificial bone substitutes have been frequently used, the ability to induce bone is limited. 3 Accordingly, less invasive and more efficient bone regeneration therapy is awaited, such as tissue engineering.
The first results of clinical bone tissue engineering were published in 2001. 4 In this study, the regeneration of long bone defects was tested using hydroxyapatite blocks together with cultured autologous bone marrow stromal cells (BMSCs). This tissue engineering-based approach proved the feasibility of this concept. The results from a preliminary clinical study of alveolar bone regeneration were published thereafter. 5 In this review, studies on clinical alveolar bone tissue engineering are summarized. Then, the problems associated with current tissue engineering were also discussed.
Bone Tissue Engineering and Stem Cells
Cells are considered as a major component of tissue engineering. Although the role of transplanted cells during bone tissue regeneration is still controversial, it has been proved that the transplanted cells could survive, proliferate, and differentiate into osteogenic phenotype. 6 There is accumulating evidence that the level and quality of regeneration is affected by the ability of transplanted cells. 7 Accordingly, it is important to establish an optimal cell culture protocol to maximize the function of osteogenic cells. Surprisingly, the BMSC ability to differentiate into osteoblast-like cells is easily diminished during passage and no bone formation was observed after several passages ( Fig. 1) . 7, 8 Furthermore, cell seeding density and the period of induction also affect in vivo osteogenic ability. It has been shown that basic fibroblast growth factor (bFGF) is beneficial to maintain in vivo osteogenic ability of BMSCs. 7 
Clinical Studies on Alveolar Bone Tissue Engineering
The results from clinical studies on alveolar bone tissue engineering using BMSCs were first reported in 2004. In this study, bone marrow-derived MSCs were mixed with platelet-rich plasma as a scaffold. 8 Bone regeneration was observed in all moderate atrophy cases. Another clinical study utilized BMSCs and hydroxyapatite granules. BMSCs were induced into osteogenic cells for 1 week and transplanted. In this study, bone formation was observed in three cases, but there was no apparent bone formation from the We have conducted a clinical study of bone tissue engineering for severe atrophy of alveolar bone. In this study, autologous BMSCs were transplanted together with plateletrich plasma gel and beta-tricalcium phosphate (b-TCP) granules as scaffolds (Fig. 2) . The results from a 2-year observation showed that bone regeneration was observed in all patients, although significant individual variations in cell growth, differentiation, and levels of bone regeneration were observed (Asahina et al., manuscript in preparation). This type of study, focused on severe atrophy cases, may prove the usefulness of alveolar bone tissue engineering. In terms of safety, no side effects or related complications have been reported, which may imply the relatively safety nature of alveolar bone tissue engineering using BMSCs.
Toward the Establishment of Reliable Alveolar Bone Tissue Engineering Using BMSCs
Although clinical studies have confirmed the feasibility and safety of alveolar bone tissue engineering using BMSCs, one of the important clinical benchmarks is the efficacy for severe atrophy cases. The results from focused studies with selected cases will provide the evidence. Another important problem is the individual variation as shown by basic and preliminary clinical studies. Since the shape and the size of bone defect vary among individuals, it might be impossible to completely eliminate such variations. Accordingly, it should be important to minimize the variation in other factors, such as cells. In terms for BMSCs, there was no significant difference in the expression of mesenchymal stem cell markers during passage. 7 In contrast, a large variation was observed in the in vivo bone forming ability among donors and during passage (Fig. 3) . 7, 8, 9 We believe the usage of early passage cells as well as growth factors (bFGF) may minimize the variation, which should be tested under clinical settings.
In spite of the number of studies and the clinical efficacy of bone tissue engineering, it is not a standard treatment at present. It is necessary to show the superiority of clinical outcome compared with standard autologous bone transplantation and allogenic (or xenogenic) transplantation. Furthermore, tissue engineering requires special facility for cell culture and there is a requirement for many safety examinations, which may also increase the cost for treatment. Those technologies, which may support the widespread use of bone tissue engineering, should be investigated.
Tissue engineering is one of the most rapidly progressing fields and alveolar bone is still an attractive target for tissue engineering. 10 The application of bone tissue engineering is not limited for dental implants and is successfully applied for other diseases such as nonunion fractures 11 and alveolar clefts.
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